期刊文献+

乌司他丁对体外循环冠脉搭桥患者凝血系统和血小板功能的影响 被引量:11

Effects of ulinastatin on coagulation and platelet function in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass
原文传递
导出
摘要 目的探讨乌司他丁对体外循环冠状动脉旁路移植术患者凝血系统、血小板功能和术后出血的影响。方法择期行体外循环(CPB)冠状动脉旁路移植术患者36例,随机分为对照组(C组,n=18)和乌司他丁组(U组,n=18)。U组将乌司他丁40万单位溶于100ml生理盐水中,自切皮开始静脉输注,30min内输注完毕,另将40万单位加入CPB预充液中,另外20万单位以4~6万单位/h速率输注至术毕,总量100万单位,C组不用乌司他丁及任何抗纤溶药物。分别于切皮前1min(基础值,T0),肝素化前1min(此时U组已用乌司他丁40万单位,T1),术毕(T2),术后6h(T3)和术后24h(T4)经颈内静脉导管采血5ml,用流式细胞仪测定血小板膜糖蛋白GPⅡb/Ⅲa和血小板α颗粒膜蛋白-140(CD62p),用比浊法测定激活部分凝血致活酶时间(APTT)、凝血酶原时间(PT)和纤维蛋白原,用硅藻土激活剂测定激活全血凝固时间(ACT)。记录患者术后24h出血量和输血量。结果组间GPⅡb/Ⅲa、CD62p和PT,以及术后24h出血量和同种输血量比较差异均无统计学意义(P〉0.05)。与基础值比较,U组APTT在T1、T3和T4均缩短(均P〈0.05)。与C组比较,U组:APTT在T1-4均缩短(均P〈0.05),体外循环中ACT缩短,补充肝素量增加(P〈0.01)。结论乌司他丁对血小板聚集和活性无影响,它能缩短APTT及肝素化后的ACT,增加CPB中补充肝素量,对内源性凝血系统有促进作用,该实验所用剂量未见减少CPB术后出血。 Objective To investigate the effects of ulinastatin (U) on coagulation, platelet function, and postoperative bleeding in patients undergoing coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB). Methods Thirty-six selective patients undergoing CABG with CPB were randomly assigned to two groups: Group U (n = 18) in which ulinastatin 4 × 10^6 U in 100 ml normal saline (NS) was infused intravenously for 30 min since skin incision with 4 × 10^6 U added to the CPB pump prime, and then 2 × 10^6 U of ulinastatin was infused intravenously at a rate of 4-6 × 10^4 U .h^-1 until the chest was closed; and control group (Group C,n = 18) in which 100 ml NS was infused without ulinastatin. Peripheral blood samples were collected 1 min before operation (T0 ), 1 min before heparinization (T1), at the end of operation ( T2 ), 6 hour after operation ( T3 ), and 24 hour after operation ( T4 ). Platelet membrane glucoprotein II Ⅱ/Ⅲ a (GP Ⅱ b/Ⅲ a) and platelet α granule membrane protein-140 (CD62p) were measured by flow cytometry. Activated partial thromboplasin time (APTT), activated coagulation time of whole blood (ACT), prothrombin time (PT), fibrinogen, and platelet number were also measured. Postoperative blood loss and allogeneic transfusion were recorded. Results There were no statistical differences in CD26p, GP Ⅱ b/Ⅲ a, and PT between the 2 groups ( all P 〉 0. 05 ). The APTF levels was significantly shortened in Group U at T1 , T3 and T4 compared to T0. The APTT levels of Group U from T1 to T4 were all significantly lower than those of Group C ( all P 〈 0. 05). The ACT levels after heparinization and during CPB in Group U were significantly shorter than those of Group C ( all P 〈 0.01 ), and the amount of added heparin during CPB of Group U was significantly higher than that of Group C ( P 〈 0. 01 ). There were not significant differences in platelet amount, fibrinogen, total amount of blood loss in 24 h after operation was 960 (420,1500) ml in group C, and 850(380, 1600) ml in group U (P 〉0. 05). The platelet count, CD26p, GPⅡ b/Ⅲ a, total amounts of blood loss and blood infusion 24 h after operation, and hemoglobin concentration between these 2 groups ( all P 〉 0. 05 ) . Conclusion Ulinastatin shortens the APTT and ACT after heparinization, increases the dose of heparin during CPB, has no effect on the expression of GP Ⅱ b-Ⅲ a and CD62p, and does not reduce postoperative blood loss.
作者 纪宏文 陈雷
出处 《中华医学杂志》 CAS CSCD 北大核心 2009年第3期175-178,共4页 National Medical Journal of China
关键词 乌司他丁 冠状动脉分流术 心肺转流术 血小板功能试验 凝血 Ulinastatin Coronary artery bypass Cardiopulmonary bypass Platelet function tests Coagulation
  • 相关文献

参考文献6

  • 1Thurer RL. Blood transfusion in cardiac surgery. Can J Anesth, 2001,48 Suppl: 6-12.
  • 2Stao Y, Ishikawa S, Otaki A, et al. Induction of acute-phase reactive substances during open-heart surgery and efficacy of ulinastatin. Inhibiting cytokinase and postoperative organ injury. Jpn J Thorac Cardiovasc Sttrg, 2000, 48:428-434.
  • 3李健,王志农,徐志云,黄盛东,乔帆.乌司他丁在体外循环术后全身炎性反应综合征治疗中的作用[J].世界急危重病医学杂志,2007,4(4):1929-1933. 被引量:3
  • 4Spiess BD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg, 2008,85:2153-2160.
  • 5Robinson KL, Marasco SF, Street AM. Practical management of anticoagulation, bleeding and blood product support for cardiac surgery. Part one: bleeding and anticoagulation issues. Heart, Lung Circulat, 2001,10 : 142-153.
  • 6纪宏文,陈雷,刘进.抑肽酶对非体外循环冠脉搭桥术病人凝血功能和血小板功能的影响[J].中华麻醉学杂志,2006,26(8):696-699. 被引量:6

二级参考文献14

  • 1Gravlee GP, Haddon WS, Rothberger HK, et al. Heparin dosing and monitoring for cardiopulmonary bypass. J Thorac Cardiovasc Surg, 1990,99 : 518-527.
  • 2Landis RC, Haskard DO, Taylor KM. New antiinflammatory and plateletpreserving effects of aprotinin. Ann Thorac Surg, 2001,72: S1808-1813.
  • 3Shigeta O, Kojima H, Jikuya T, et al. Aprotinin inhibits plasmininduced platelet activation during cardiopulmonary bypass. Circulation,1997,96 : 569-574.
  • 4Despotis GJ, Gravlee G, Filos K, et al. Antieoagulation monitoring during cardiac surgery: a review of current and emerging techniques.Anesthesiology, 1999, 91 : 1122-1151.
  • 5Landis RC, Asimakopoulos G, Poullis M, et alThe antithrombotie and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg,2001, 72:2169-2175.
  • 6Rich JB. The efficacy and safety of aprotinin use in cardiac surgery. Ann Thorac Surg, 1998, 66(5 Suppl) :S6-11.
  • 7Sodha NL, Boodhwani M, Bianchi C, et al. Aprotinin in Cardiac Surgery. Expert Rev Cardiovasc Ther, 2006, 4:151-160.
  • 8Hardy JF. Pharmacological strategies for blood conservation in cardiac surgery:erythropoietin and antifibrinolytics. Can J Anesth, 2001, 48:S24-S31.
  • 9Peter DC, Noble S. Aprotinin an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery.Drug, 1999,57:233-259.
  • 10Englberger L, Markart P, Eckstein FS, et al. Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery. Eur J Cardiothorac Surg, 2002, 22 : 545-551.

共引文献7

同被引文献109

引证文献11

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部